Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Deregulation of Adaptive T Cell Immunity in Multiple Myeloma: Insights Into Mechanisms and Therapeutic Opportunities
Noémie Leblay, Ranjan Maity, Fajer Hasan, et al.
Frontiers in Oncology (2020) Vol. 10
Open Access | Times Cited: 39

Showing 1-25 of 39 citing articles:

Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study
Philippe Moreau, Michel Attal, Cyrille Hulin, et al.
The Lancet (2019) Vol. 394, Iss. 10192, pp. 29-38
Open Access | Times Cited: 824
Current state and next-generation CAR-T cells in multiple myeloma
Salomon Manier, Tiziano Ingegnere, Guillaume Escure, et al.
Blood Reviews (2022) Vol. 54, pp. 100929-100929
Open Access | Times Cited: 80
Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel
Noopur Raje, Kenneth C. Anderson, Hermann Einsele, et al.
Blood Cancer Journal (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 76
Multiomic analysis of cytokines in immuno-oncology
Vladimir Jurišić
Expert Review of Proteomics (2020) Vol. 17, Iss. 9, pp. 663-674
Closed Access | Times Cited: 136
Subclone-specific microenvironmental impact and drug response in refractory multiple myeloma revealed by single‐cell transcriptomics
Stephan M. Tirier, Jan‐Philipp Mallm, Simon Steiger, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 96
Belantamab Mafodotin (GSK2857916) Drives Immunogenic Cell Death and Immune-mediated Antitumor ResponsesIn Vivo
Rocío Montes de, Alireza Alavi, Nick Vitali, et al.
Molecular Cancer Therapeutics (2021) Vol. 20, Iss. 10, pp. 1941-1955
Open Access | Times Cited: 77
Targeting stromal cell sialylation reverses T cell-mediated immunosuppression in the tumor microenvironment
Hannah Egan, Oliver Treacy, Kevin Lynch, et al.
Cell Reports (2023) Vol. 42, Iss. 5, pp. 112475-112475
Open Access | Times Cited: 37
Inhibition of Arginase 1 Liberates Potent T Cell Immunostimulatory Activity of Human Neutrophil Granulocytes
Verena Vonwirth, Yagmur Bülbül, Anke Werner, et al.
Frontiers in Immunology (2021) Vol. 11
Open Access | Times Cited: 41
Just scratching the surface: novel treatment approaches for multiple myeloma targeting cell membrane proteins
Paola Neri, Noémie Leblay, Holly Lee, et al.
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 8, pp. 590-609
Closed Access | Times Cited: 7
Progress and prospect of ASCT combined with CAR-T therapy in the treatment of multiple myeloma
S. Yuan, Ying Chen, Huasheng Liu
Therapeutic Advances in Hematology (2024) Vol. 15
Open Access | Times Cited: 6
Mechanisms of resistance to bispecific T cell engagers in multiple myeloma and their clinical implications
Éric Letouzé, Philippe Moreau, Nikhil Munshi, et al.
Blood Advances (2024) Vol. 8, Iss. 11, pp. 2952-2959
Open Access | Times Cited: 6
Multiple Myeloma Insights from Single-Cell Analysis: Clonal Evolution, the Microenvironment, Therapy Evasion, and Clinical Implications
Sihong Li, Jiahui Liu, Madeline Peyton, et al.
Cancers (2025) Vol. 17, Iss. 4, pp. 653-653
Open Access
Progress of immune senescence in multiple myeloma treatment resistance
Yanan Jia, Lixiang Yan, Chenyang Fan, et al.
Discover Oncology (2025) Vol. 16, Iss. 1
Open Access
Chimeric antigen receptor T cell therapies for multiple myeloma
Chao Wu, Lina Zhang, Qierra R. Brockman, et al.
Journal of Hematology & Oncology (2019) Vol. 12, Iss. 1
Open Access | Times Cited: 37
Transient regulatory T-cell targeting triggers immune control of multiple myeloma and prevents disease progression
Julia Dahlhoff, Hannah Manz, Tim Steinfatt, et al.
Leukemia (2021) Vol. 36, Iss. 3, pp. 790-800
Open Access | Times Cited: 32
Unveiling Extramedullary Myeloma Immune Microenvironment: A Systematic Review
Kassiani Boulogeorgou, Maria Papaioannou, Sofia Chatzileontiadou, et al.
Cancers (2025) Vol. 17, Iss. 7, pp. 1081-1081
Open Access
Current use of bispecific antibodies to treat multiple myeloma
Holly Lee, Paola Neri, Nizar J. Bahlis
Hematology (2023) Vol. 2023, Iss. 1, pp. 332-339
Closed Access | Times Cited: 10
The Role of 1q Abnormalities in Multiple Myeloma: Genomic Insights, Clinical Implications, and Therapeutic Challenges
Zachary M. Avigan, Constantine S. Mitsiades, Alessandro Laganà
Seminars in Hematology (2024)
Closed Access | Times Cited: 3
Bispecific antibodies for the treatment of hematologic malignancies: The magic is T-cell redirection
Geoffrey Shouse
Blood Reviews (2024), pp. 101251-101251
Closed Access | Times Cited: 2
Understanding the Mechanisms of Resistance to T Cell-based Immunotherapies to Develop More Favorable Strategies in Multiple Myeloma
Sungwoo Ahn, Noémie Leblay, Paola Neri
HemaSphere (2021) Vol. 5, Iss. 6, pp. e575-e575
Open Access | Times Cited: 17
Activated Tim-3/Galectin-9 participated in the development of multiple myeloma by negatively regulating CD4 T cells
Rui Zhang, Shuang Chen, Tingting Luo, et al.
Hematology (2023) Vol. 29, Iss. 1
Open Access | Times Cited: 6
Harnessing the Immune System to Fight Multiple Myeloma
Jakub Krejcik, Mike Bogetofte Barnkob, Charlotte Guldborg Nyvold, et al.
Cancers (2021) Vol. 13, Iss. 18, pp. 4546-4546
Open Access | Times Cited: 13
Immune microenvironment characteristics in multiple myeloma progression from transcriptome profiling
Jin Wang, Yi Hu, Habib Hamidi, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 8
T-Cell-Based Cellular Immunotherapy of Multiple Myeloma: Current Developments
Gary Simmons, Omar Castaneda Puglianini
Cancers (2022) Vol. 14, Iss. 17, pp. 4249-4249
Open Access | Times Cited: 8
CAR-T Therapy in Multiple Myeloma: Looking Beyond
Gianluca Maiorana, Giusy Antolino, Giacinto La Verde, et al.
Hemato (2024) Vol. 5, Iss. 2, pp. 180-198
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top